# Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs — General Considerations - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/bioavailability-and-bioequivalence-studies-submitted-in-ndas-or-inds-general-considerations/0cbdcef4-1b6b-45e5-8563-de1bb0a4e001

> FDA guidance document: Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs — General Considerations. Issue date: March 18, 2014. Get complete insights and analysis.

---

## Details

- Title: Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs — General Considerations
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2014-03-18
- Last Changed: 2020-04-29
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2014-D-0204">FDA-2014-D-0204</a>

## Related Documents

- [Clinical Pharmacology Considerations for Peptide Drug Products](https://www.globalkeysolutions.net/guidances/guidance-document/clinical-pharmacology-considerations-for-peptide-drug-products/1609c8ed-4d50-4235-8a00-9c63176affe8)
- [Alcoholism:  Developing Drugs for Treatment](https://www.globalkeysolutions.net/guidances/guidance-document/alcoholism-developing-drugs-for-treatment/5dd607ce-ea00-4415-bc0a-e05b7963322b)
- [Data Integrity for In Vivo Bioavailability and Bioequivalence Studies](https://www.globalkeysolutions.net/guidances/guidance-document/data-integrity-for-in-vivo-bioavailability-and-bioequivalence-studies/04d979b3-3f1d-4515-b9c1-f1a8fb7fb19b)